Proven and clinically meaningful efficacy data

At week 12

Many moderate to severe HS patients achieved HiSCR.1,3,7
HiSCR requires:

≥ 50% reduction in the total abbscess and inflammatory nodule count relative to baseline


no increase in abscess count relative to baseline


no increase in draining fistula count relative to baseline

Well-studied safety profile

well-studied HUMIRA HS safety

The safety profile of HS was consistent with the safety profile of HUMIRA overall—no new safety signals in adults.1,4,5

Dosing for adults and adolescents (≥12 yrs)


  • Once a week dosing schedule following initial doses for adults + adolescents ≥60 kg (132 lbs)1
  • Every-other-week dosing schedule following initial dose for adolescents ≥30kg to <60 kg (66 lbs to <132 lbs)1


HUMIRA Citrate-free

No citrate buffers, thinner needle, less pain immediately following injection compared with the HUMIRA 40 mg/0.8 mL presentation.8†§

HUMIRA Citrate-free is available to all indicated patients in the United States. HUMIRA Citrate-free features the same safety and efficacy profile of HUMIRA you've come to count on.
§Injection site pain immediately following injection as measured using a 0-10 cm Visual Analog Scale: HUMIRA 40 mg/0.4 mL vs HUMIRA 40 mg/0.8 mL.